Published in Br J Pharmacol on March 01, 2000
ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut (2003) 1.10
Sucralose, a synthetic organochlorine sweetener: overview of biological issues. J Toxicol Environ Health B Crit Rev (2013) 1.06
Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice. Br J Pharmacol (2002) 0.80
Influence of intermittent hypoxia on myocardial and hepatic P-glycoprotein expression in a rodent model. Pharmacotherapy (2009) 0.78
Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Des Devel Ther (2014) 0.78
In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients. Eur J Nutr (2010) 0.77
Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol (2015) 0.76
Screening candidate anticancer drugs for brain tumor chemotherapy: pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues. Invest New Drugs (2012) 0.76
Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats. Drug Des Devel Ther (2016) 0.75
Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates. Front Pharmacol (2015) 0.75
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important? Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev (1993) 4.69
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun (1991) 3.25
Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev (1990) 2.88
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog (1995) 2.25
CYP3A gene expression in human gut epithelium. Pharmacogenetics (1994) 1.66
Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest (1998) 1.65
Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther (1990) 1.60
A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci U S A (1988) 1.60
Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci (1993) 1.47
Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest (1996) 1.37
Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem (1993) 1.30
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
Fluoroquinolone (ciprofloxacin) secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol (1997) 1.13
Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs (1997) 1.13
Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol (1997) 1.10
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther (1995) 1.05
Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos (1995) 1.03
Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol (1996) 1.02
Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev (1999) 1.01
Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res (1993) 1.01
Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther (1998) 1.00
Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B. Hepatology (1998) 1.00
Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res (1998) 0.99
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? Semin Cancer Biol (1997) 0.89
Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol (1996) 0.87
Transepithelial secretion, cellular accumulation and cytotoxicity of vinblastine in defined MDCK cell strains. Biochim Biophys Acta (1993) 0.81
The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug Metab Dispos (1992) 0.80
In vitro and in vivo evaluations of intestinal barriers for the zwitterion L-767,679 and its carboxyl ester prodrug L-775,318. Roles of efflux and metabolism. Drug Metab Dispos (1998) 0.80
Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers. Pharm Res (1998) 0.80
Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line. Jpn J Cancer Res (1995) 0.79
MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver. Cancer Res (1996) 0.78
Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers. J Pharm Sci (1997) 0.78
CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos (1996) 0.78
Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci (1979) 4.96
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J Pharmacol Exp Ther (1991) 2.55
HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant (2007) 2.50
PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol (1992) 2.43
Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther (2012) 2.38
Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog (1995) 2.25
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17
Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm (1973) 2.16
Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther (1976) 2.08
Gender effects in pharmacokinetics and pharmacodynamics. Drugs (1995) 1.94
The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet (2001) 1.72
PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol (1993) 1.69
Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant (2007) 1.69
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther (2006) 1.69
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos (1992) 1.59
Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem (1998) 1.58
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther (1997) 1.55
Elderly, conscious patients have an accentuated hypotensive response to nitroglycerin. Anesthesiology (1992) 1.53
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit (2001) 1.53
Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm (1980) 1.50
Pharmacokinetics/pharmacodynamics of furosemide in man: a review. J Pharmacokinet Biopharm (1979) 1.47
Effect of route of administration and distribution on drug action. J Pharmacokinet Biopharm (1978) 1.44
Application of clearance concepts to the assessment of exposure to lead in drinking water. Am J Public Health (1989) 1.43
[Structure-activity relationship of N-methyl-3-pyrroline and N-methyl-pyrrolidine-3-carboxylic acid]. Arzneimittelforschung (1971) 1.40
Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos (2000) 1.40
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos (1995) 1.39
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci (1998) 1.37
Study of the contractile effect of 5-hydroxytryptamine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch Pharmacol (1985) 1.36
[Structure-activity relationships of unsaturated esters of arecaidine and dihydroarecaidine]. Arzneimittelforschung (1973) 1.35
Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev (1992) 1.32
Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit (1995) 1.30
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther (1995) 1.28
Selective antagonism by PPADS at P2X-purinoceptors in rabbit isolated blood vessels. Br J Pharmacol (1994) 1.27
Vasoconstrictor and vasodilator responses to various agonists in the rat perfused mesenteric arterial bed: selective inhibition by PPADS of contractions mediated via P2x-purinoceptors. Br J Pharmacol (1994) 1.27
Renal function in the elderly: impact of hypertension and cardiac function. Kidney Int (1997) 1.27
Interaction of metoprolol, propranolol and atenolol with concurrent administration of cimetidine. Klin Wochenschr (1982) 1.26
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther (1995) 1.25
Interaction of cimetidine with metoprolol, propranolol, or atenolol. Lancet (1981) 1.22
Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol (1996) 1.20
Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev (2001) 1.20
Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther (1992) 1.19
Fluorimetric determination of atenolol in plasma and urine by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.18
Investigation of the actions of PPADS, a novel P2x-purinoceptor antagonist, in the guinea-pig isolated vas deferens. Br J Pharmacol (1994) 1.18
Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl (2000) 1.18
Attenuation of furosemide's diuretic effect by indomethacin: pharmacokinetic evaluation. J Pharmacokinet Biopharm (1979) 1.17
Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17
Fluorimetric determination of oxprenolol in plasma by direct evaluation of thin-layer chromatograms. J Chromatogr (1979) 1.17
p-fluoro-hexahydro-sila-difenidol: the first M2 beta-selective muscarinic antagonist. Eur J Pharmacol (1988) 1.16
Pharmacokinetics of cefamandole using a HPLC assay. J Pharmacokinet Biopharm (1978) 1.15
Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update. J Pharmacokinet Biopharm (1989) 1.15
Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin Pharmacol Ther (2008) 1.14
Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int (1999) 1.14
Antimuscarinic action of methoctramine, a new cardioselective M-2 muscarinic receptor antagonist, alone and in combination with atropine and gallamine. Eur J Pharmacol (1987) 1.13
Liquid-chromatographic measurement of endogenous and exogenous glucocorticoids in plasma. Clin Chem (1979) 1.13
Pharmacological characterization of the vascular muscarinic receptors mediating relaxation and contraction in rabbit aorta. J Pharmacol Exp Ther (1991) 1.12
Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen, 3'-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry. Adv Exp Med Biol (2001) 1.12
Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J Pharmacokinet Biopharm (1975) 1.10
Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol (1995) 1.10
Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos (1999) 1.09
The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther (2001) 1.09
Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors. J Biol Chem (1994) 1.07
In vitro evaluation of the disposition of A novel cysteine protease inhibitor. Drug Metab Dispos (2000) 1.06
Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc (2001) 1.06
General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics. J Pharm Sci (1972) 1.04
Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem (1996) 1.02
Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes. Eur J Pharmacol (1989) 1.01
Prednisolone pharmacodynamics assessed by inhibition of the mixed lymphocyte reaction. Transplantation (1982) 1.00
The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther (1977) 1.00
Muscarinic receptors mediating acid secretion in isolated rat gastric parietal cells are of M3 type. Gastroenterology (1990) 1.00
Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther (1998) 1.00
Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol (1985) 0.99
Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med (1979) 0.99
Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin Pharmacol Ther (2007) 0.99
Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res (1999) 0.99
Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob Agents Chemother (1987) 0.99
Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol (2001) 0.98
Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos (1999) 0.98
Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther (1977) 0.98
Variable glyceryl dinitrate formation as a function of route of nitroglycerin administration. Clin Pharmacol Ther (1987) 0.98
Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm (1980) 0.97
Inhibitory action of PPADS on relaxant responses to adenine nucleotides or electrical field stimulation in guinea-pig taenia coli and rat duodenum. Br J Pharmacol (1995) 0.96
Presynaptic muscarinic receptors mediating inhibition of neurogenic contractions in rabbit vas deferens are of the ganglionic M1-type. Eur J Pharmacol (1988) 0.96
Improved gas chromatographic assay for the simultaneous determination of nitroglycerin and its mono- and dinitrate metabolites. J Chromatogr (1992) 0.96
Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokinet Biopharm (1980) 0.96
The bioavailability of oral nitroglycerin. J Pharm Sci (1986) 0.96
o-Methoxy-sila-hexocyclium: a new quaternary M1-selective muscarinic antagonist. Eur J Pharmacol (1988) 0.95
Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther (1997) 0.95
Influence of ranitidine on plasma metoprolol and atenolol concentrations. Br Med J (Clin Res Ed) (1983) 0.95
[On the microbiological conversion of N-containing substrates. 4. On the microbiological conversion of 5-hydroxyindole through Clavic eps purpurea, Cordyceps militaris and Aspergillus oryzae]. Arch Pharm Ber Dtsch Pharm Ges (1968) 0.95
General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm (1988) 0.95
Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts. Pharm Res (1989) 0.95